Melanotan peptide (Melanotan I)
Melanotan peptide, often referred to as Melanotan I, is a synthetic peptide developed as an analogue of a naturally occurring hormone involved in skin pigmentation and melanocyte activity. It was originally studied for its ability to stimulate melanin production and potentially protect the skin from ultraviolet (UV) radiation.
Melanotan I is structurally related to Alpha-melanocyte-stimulating hormone, a hormone that regulates melanin production through activation of melanocortin receptors in the skin.
A pharmaceutical derivative of this peptide was later developed as Afamelanotide, which has received regulatory approval in certain regions for specific medical conditions involving photosensitivity. Because of its biological activity in melanocortin signaling pathways, melanotan has been studied in research related to dermatology, photoprotection, and pigmentation biology.
How Melanotan peptide works
Melanotan peptide acts as an agonist of melanocortin receptors, particularly the MC1 receptor, which plays a key role in regulating melanin production in the skin. Activation of this pathway may:
stimulate melanin production in melanocytes
increase skin pigmentation independent of UV exposure
enhance the skin’s natural protective response to ultraviolet radiation
Melanin helps absorb and dissipate UV radiation, which is why researchers initially investigated melanocortin analogues as potential agents for photoprotection and skin damage prevention.
Because melanocortin receptors also influence other physiological systems, these compounds may interact with additional biological pathways related to appetite, metabolism, and endocrine signaling.
Clinical trials and evidence
Melanotan I and related melanocortin analogues have been investigated in clinical and experimental studies exploring their effects on pigmentation and photosensitivity. Research has examined:
stimulation of melanin production in human skin
potential protection against UV-induced skin damage
therapeutic applications for photosensitive skin disorders
Development of melanocortin analogues eventually led to the creation of afamelanotide, which has been studied in clinical trials and approved in some regions for conditions such as erythropoietic protoporphyria, a rare disorder causing extreme sensitivity to sunlight.
However, melanotan itself has not been widely approved as a pharmaceutical drug, and most available information comes from research and early clinical investigations.
Possible side effects of Melanotan peptide:
Because melanotan activates melanocortin receptors throughout the body, it may produce a range of physiological effects. Reported or possible side effects may include:
nausea
flushing
increased skin pigmentation
darkening of existing moles or freckles
fatigue
As with other investigational peptides affecting hormonal signaling pathways, the long-term safety profile has not been fully established outside controlled clinical settings.